announces that it will present preclinical data on its next generation autotaxin inhibitor, IOA-289, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place on November 10 ...

DIONE-01 is a two-part, first-in-human dose study evaluating IOA-244 in solid tumors and hematologic malignancies. Data from the first part of the study will be presented at ESMO-IO via a poster ...

The data presented at ASCO will show that IOA-244 has potentially best-in-class tolerability and impressive overall survival in refractory uveal melanoma patients. We are looking forward to ...